Introduction Lupin Ltd., established in 1968 by Desh Bandhu Gupta, is a multinational pharmaceutical company headquartered in Mumbai, India that mainly focuses on innovation. The company specializes in producing both branded and generic formulations, as well as biotechnology products and active pharmaceutical ingredients. It provides services to various industries, including cardiovascular, diabetology, asthama, anti-tuberculosis, cephalosporins and so on. Lupin Ltd. operates in diverse geographical areas, such as India, the USA, Japan, and other regions. |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 16 |
Biosimilar | 5 |
Colony-stimulating factors | 3 |
Chemical drugs | 2 |
Monoclonal antibody | 1 |
Target |
Mechanism P2Y12 receptor agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. KR |
First Approval Date01 Aug 2010 |
Target |
Mechanism β2-adrenergic receptor agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date06 Oct 2006 |
Target |
Mechanism β2-adrenergic receptor agonists |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date11 Mar 2005 |
Start Date01 Nov 2023 |
Sponsor / Collaborator |
Start Date30 Oct 2023 |
Sponsor / Collaborator |
Start Date30 Sep 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Cefadroxil ( PBPs ) | Pharyngitis More | Approved |
Clopidogrel besylate ( P2Y12 receptor ) | Stroke More | Approved |
Fenofibrate ( PPARα ) | Hypertriglyceridemia More | Approved |
Secnidazole | Bacterial Vaginosis More | Approved |
Teriparatide biosimilar (Lupin) ( PTH1R ) | Primary osteoporosis More | Approved |